Literature DB >> 18521083

Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells.

T Maimets1, I Neganova, L Armstrong, M Lako.   

Abstract

p53 Is an important regulator of normal cell response to stress and frequently mutated in human tumours. Here, we studied the effects of activation of p53 and its target gene p21 in human embryonic stem cells. We show that activation of p53 with small-molecule activator nutlin leads to rapid differentiation of stem cells evidenced by changes in cell morphology and adhesion, expression of cell-specific markers for primitive endoderm and trophectoderm lineages and loss of pluripotency markers. p21 is quickly and dose-dependently activated by nutlin. It can also be activated independently from p53 by sodium butyrate, which leads to the differentiation events very similar to the ones induced by p53. During differentiation, the activating phosphorylation site of CDK2 Thr-160 becomes dephosphorylated and cyclins A and E become degraded. The target for CDK2 kinase in p53 molecule, Ser-315, also becomes dephosphorylated. We conclude that the main mechanism responsible for differentiation of human stem cells by p53 is abolition of S-phase entry and subsequent stop of cell cycle in G0/G1 phase accompanied by p21 activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18521083     DOI: 10.1038/onc.2008.166

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  58 in total

1.  p53 in stem cells.

Authors:  Valeriya Solozobova; Christine Blattner
Journal:  World J Biol Chem       Date:  2011-09-26

Review 2.  Driving apoptosis-relevant proteins toward neural differentiation.

Authors:  Susana Solá; Márcia M Aranha; Cecília M P Rodrigues
Journal:  Mol Neurobiol       Date:  2012-07-01       Impact factor: 5.590

3.  Nutlin-3 down-regulates retinoblastoma protein expression and inhibits muscle cell differentiation.

Authors:  Erica M Walsh; MengMeng Niu; Johann Bergholz; Zhi-Xiong Jim Xiao
Journal:  Biochem Biophys Res Commun       Date:  2015-04-12       Impact factor: 3.575

4.  Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.

Authors:  Rit Vatsyayan; Jyotsana Singhal; Lokesh Dalasanur Nagaprashantha; Sanjay Awasthi; Sharad S Singhal
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

Review 5.  The emerging functions of the p53-miRNA network in stem cell biology.

Authors:  Chao-Po Lin; Yong Jin Choi; Geoffrey G Hicks; Lin He
Journal:  Cell Cycle       Date:  2012-06-01       Impact factor: 4.534

Review 6.  Molecular mechanisms controlling the cell cycle in embryonic stem cells.

Authors:  Essam M Abdelalim
Journal:  Stem Cell Rev Rep       Date:  2013-12       Impact factor: 5.739

7.  Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs.

Authors:  Erica Ungewitter; Heidi Scrable
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

8.  Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.

Authors:  Wei Du; Junfeng Wu; Erica M Walsh; Yujun Zhang; Chang Yan Chen; Zhi-Xiong Jim Xiao
Journal:  J Biol Chem       Date:  2009-07-31       Impact factor: 5.157

9.  Copy number variation and selection during reprogramming to pluripotency.

Authors:  Samer M Hussein; Nizar N Batada; Sanna Vuoristo; Reagan W Ching; Reija Autio; Elisa Närvä; Siemon Ng; Michel Sourour; Riikka Hämäläinen; Cia Olsson; Karolina Lundin; Milla Mikkola; Ras Trokovic; Michael Peitz; Oliver Brüstle; David P Bazett-Jones; Kari Alitalo; Riitta Lahesmaa; Andras Nagy; Timo Otonkoski
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

10.  Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.

Authors:  Rachel Sarig; Noa Rivlin; Ran Brosh; Chamutal Bornstein; Iris Kamer; Osnat Ezra; Alina Molchadsky; Naomi Goldfinger; Ori Brenner; Varda Rotter
Journal:  J Exp Med       Date:  2010-08-09       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.